Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

BDSI Developing Long-Acting Vaccine for Pain Treatment

By Drug Discovery Trends Editor | October 28, 2014

BioDelivery Sciences International Inc. (BDSI) has entered into an exclusive agreement with Evonik Corporation to develop and commercialize a proprietary, injectable microparticle formulation of buprenorphine potentially capable of providing 30 days of continuous therapy following a single subcutaneous injection.

While BDSI plans to pursue an indication for the maintenance treatment of opioid dependence, the company has also secured the rights and plans to develop a product for the treatment of chronic pain in patients requiring continuous opioid therapy.  BDSI has also secured options to license Evonik-owned intellectual property related to these products.

It is estimated that approximately 2.5 million people in the U.S. are dependent on prescription opioids or heroin. Despite the availability of effective treatments, including Bunavail (buprenorphine and naloxone) buccal film, challenges remain regarding patient adherence to long-term buprenorphine treatment, which is critical to successfully manage opioid dependence.

“Given our significant experience with buprenorphine in both opioid dependence and chronic pain, we believe this is an ideal opportunity for BDSI to extend our franchise in both of these areas as the need remains high,” said Dr. Andrew Finn, executive vice president of product development for BDSI.  “We look forward to working closely with Evonik to expeditiously complete formulation development work and move the product into the clinic late next year.  Since this will be a 505(b)(2) development program, we believe there may be an opportunity to move toward an NDA submission for opioid dependence in approximately three years time.” 

“Evonik is pleased to work with BDSI on the development of this novel long-acting buprenorphine product,” said Dr. Jean-Luc Herbeaux, head of Evonik’s Global Health Care Business Line.  “With its broad range of competencies in API and drug delivery systems, Evonik strives to support customers in the development and launch of novel medical treatments.  Using our proprietary FormEZE microparticle technology and Resomer biomaterials, this pharmaceutical will be manufactured at our state-of-the-art facility in Birmingham, Alabama.”

“The potential availability of a long-acting formulation of buprenorphine has the opportunity to significantly advance the treatment of opioid dependence and furthers our commitment to this underserved treatment area,” said Dr. Mark A. Sirgo, president and chief executive officer.  “Not only would a single monthly injection provide an opportunity to substantially improve adherence to buprenorphine treatment, which is a formidable problem for many patients, it could also help to eliminate the problem of diversion.  We also believe this will be an outstanding companion product to BUNAVAIL and, if approved, provides another product for our existing sales team.”

As part of the agreement, BDSI will have the right to license the product(s) following the attainment of Phase I ready formulations.  At that point, Evonik could receive downstream payments for milestones related to regulatory filings and subsequent NDA approvals as well as product royalties.  Evonik has the exclusive rights to develop the formulation and manufacture the product(s).

Date: October 28, 2014

Source: BioDelivery Sciences International


Filed Under: Drug Discovery

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority
Portrait photo of Pfizer EVP and Medtronic board member Lidia Fonseca
Medtronic appoints Pfizer EVP as independent board director

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50